• Route

  • Cluster question

  • Organisation

Research initiatives

PM.20.056 – Optimal survival and quality of life in metastatic colorectal cancer with irinotecan dosing based on UGT1A1 genotype and gut microbiome enzyme activity including a dietary intervention

Route: Personalised medicine: the individual at the centre

cluster question: 095 How can we personalise health care, for example by using biomarkers?

Problem description: Irinotecan-based systemic therapy is one of the main chemotherapeutic agents used for metastatic colorectal cancer (mCRC). It can […]

View the initiative